Cumberland Pharmaceuticals Inc. (CPIX)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$7.09−4.06%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $106M
- Forward P/E
- 50.6
- 52-week range
- $1.85 – $9.28
- 52-week change
- +139.16%
- EPS (trailing)
- −$0.62
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $44.5M (+17.57%)
- Net income
- −$2.8M
- Operating margin
- −6.3%
- Diluted EPS
- −$0.19
- Free cash flow
- $4.8M
From the company’s annual report on SEC EDGAR.
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection.
Headquarters: Nashville, United States · 88 employees · cumberlandpharma.com